SEC Form 4 · accession 0001104659-17-071740
Aralez Pharmaceuticals Inc. · ARLZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Kaseta
Officer — Interim CFO
Period of report
Nov 30, 2017
Accepted (ET)
Dec 4, 2017 · 7:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001660719
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $1.51 | Nov 30, 2017 | A | 25,000 | A | — | Nov 30, 2027 | Common Shares, without par value | 25,000 | 25,000 | D |
Explanation of responses
- F1The option vests as to 25% of the shares on November 30, 2018, and the remainder vests in substantially equal monthly installments over the 36 months immediately following such date, subject to continued employment or service to the Company.